Cargando…
Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells
Imatinib, a multitargeted receptor tyrosine kinase inhibitor, is used as the standard initial therapy against inoperable gastrointestinal stromal tumor (GIST). However, GIST can acquire resistance to imatinib within several years of therapy. The development of oncolytic reovirus as an anticancer age...
Autores principales: | Inagaki, Yusuke, Kubota, Eiji, Mori, Yoshinori, Aoyama, Mineyoshi, Kataoka, Hiromi, Johnston, Randal N., Joh, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777799/ https://www.ncbi.nlm.nih.gov/pubmed/29383187 http://dx.doi.org/10.18632/oncotarget.23361 |
Ejemplares similares
-
Oncolytic Reovirus in Canine Mast Cell Tumor
por: Hwang, Chung Chew, et al.
Publicado: (2013) -
The oncolytic effects of reovirus in canine solid tumor cell
lines
por: IGASE, Masaya, et al.
Publicado: (2015) -
The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006) -
Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus Variants
por: Mohamed, Adil, et al.
Publicado: (2015) -
Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020)